THCV Tetrahydrocannabivarin
Grades as of 9 August 2026 · check cbgatlas.com/card/thcv
Specimen
- Formula
- C₁₉H₂₆O₂
- Molar mass
- ≈ 286.4 g/mol
- Class
- Propyl (varin) homolog of THC
- Origin
- CBGVA → THCA synthase → THCVA → THCV. Its own acid, not a trimmed THC
- Cannabinoid receptors
- Direction changes with dose (see mechanism)
- Evidence base
- Tested in people. The metabolic trial missed its primary endpoint
- Approved use
- None, for any indication, in any jurisdiction
- Registry status
- 1 verified review · its registry summary leaves THCV out
- CAS
- not recorded on the site
- Studies in our registry
- 1
In the family
THC’s propyl (varin) analog, made on the plant’s parallel three-carbon line.
The record cited in prose · ungraded
Established
- Chemical identity C₁₉H₂₆O₂ (≈ 286.4 g/mol).
- It comes from its own acid, not from THC The plant builds THCV on a parallel line of its own.
- Its receptor directions are published, with a dose condition A 2008 review states them in its abstract, and we quote them word for word: in CB1-expressing tissues THCV blocks cannabinoid agonists, and in live animals it acts as a CB1 antagonist or, at higher doses, as a CB1 agonist.
Not yet established
- Any approved use for diabetes, weight loss or appetite Not established.
- The metabolic trial's own primary endpoint Tested, and it failed.
- Appetite suppression, in a person Not established, and it is the claim THCV is sold on.
Cardiovascular note grade: grade: Hypothesized
CBG may influence blood pressure via α2-adrenoceptor activity; the direction and magnitude of any human effect are uncharacterized. Mechanistic plausibility only: the receptor activity has been measured in the laboratory, and no study has measured a blood-pressure effect of CBG in a person. A CBG finding, printed here because THCV shares the family; it does not transfer to THCV. If you take blood-pressure medication or have a cardiovascular condition, consult a clinician first.
Informational only, not medical advice. Nothing here diagnoses, treats, cures or prevents any disease. Report a safety event. Peregrine Biopharma funds the platform and holds no editorial authority.